MedPath

PhaseI/II study of neoadjuvant TS-1+CDDP with concurrent radiation for biliary tract cancer

Phase 1
Conditions
Biliary tract cancer
Registration Number
JPRN-UMIN000009028
Lead Sponsor
Keio University School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

(1)bowel movement control is difficult, because of watery diarrhea and chronic diarrhea. (2)administered flucytosine, Phenytoin, Warfarin potassium (3)Pleural effusion or ascitic fluid accumulates (4)with clinically important infection (5)has active carcinoma except carcinoma in situ (6)with gastrointestinal active ulcer (7)sever complication(Heart failure, renal failure,liver failure,Intestinal paralysis,uncontrollable diabetes etc) (8)severe mental disorder (9)pregnant women or during the nursing, women who like be pregnant and willing to get pregnant,men who want his partner to be pregnant (10)doctors decision not to be registered to this study

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
(PhaseI) Estimate the maximum tolerated dose(MTD) and recommended dose(RD) (PhaseII) R0 resection rate
Secondary Outcome Measures
NameTimeMethod
(PhaseI) Response Rate, Adverse events (PhaseII) Overall survival, 2 year survival rate, Progression Free Survival(PFS), Response Rate(RR), Limited operation rate, adverse events
© Copyright 2025. All Rights Reserved by MedPath